This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SGO 2024
Presentations
Seagen Development Pipeline
Session Info Card
Tisotumab Vedotin | Cervical Cancer | Abstract #428204
Seeing Health Disparities in Cervical Cancer: Mapping Behavioral and Socioeconomic Drivers of Geographic Dispersion of Disease Burden with the Geo-Analyzer Tool
Tisotumab Vedotin | Cervical Cancer | Abstract #568638
Efficacy and Safety of Tisotumab Vedotin Versus Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A Global, Randomized, Open-Label, Phase 3 Study
Tisotumab Vedotin | Cervical Cancer | Abstract #448275
Patients with advanced cervical cancer value disease control and overall survival in treatment decision-making: a US patient preference study
Disitamab Vedotin | Solid Tumors | Abstract #481945
Phase 2 Basket Study of Disitamab Vedotin in Patients With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors That Express HER2: Ovarian and Endometrial Cancer Cohorts (DV-005; Trial in Progress)